CRBP Corbus Pharmaceuticals Hold...

Nasdaq corbuspharma.com


$ 16.91 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 04:14:26 EDT
QQQ $ 603.13 $ 0.00 (0 %)
DIA $ 464.59 $ 0.00 (0 %)
SPY $ 666.16 $ 0.00 (0 %)
TLT $ 91.05 $ 0.00 (0 %)
GLD $ 387.33 $ 0.00 (0 %)
$ 16.25
$ 16.27
$ 16.50 x 12
$ 17.11 x 30
-- - --
$ 4.64 - $ 20.77
160,302
na
199.15M
$ 1.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-12-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-07-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-12-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-08-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-12-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-28-2016 12-31-2015 10-K
40 11-10-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 corbus-pharmaceuticals-releases-abstract-for-its-phase-12-oncology-study-ahead-of-presentation-at-esmo-congress-2025-abstract-includes-safety-data-from-70-participants

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced today t...

 hc-wainwright--co-reiterates-buy-on-corbus-pharmaceuticals-maintains-40-price-target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains...

 oppenheimer-maintains-outperform-on-corbus-pharmaceuticals-lowers-price-target-to-53

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target ...

 corbus-pharmaceuticals-q2-eps-144-beats-152-estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate o...

 corbus-pharmaceuticals-announces-that-an-abstract-on-updated-clinical-data-from-its-phase-12-clinical-study-of-crb-701-has-been-accepted-for-presentation-as-a-poster-at-the-european-society-for-medical-oncology--congress-2025--october-17-21-2025-in-berlin-germany

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, announced today t...

 corbus-pharma-initiates-multiple-ascending-dose-portion-of-phase-1-trial-for-crb-913-peripherally-restricted-cb1-inverse-agonist-for-obesity-treatment-mad-study-on-track-for-completion-in-q3-2025

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION